Poor Sit-to-Stand Performance in Adolescent and Young Adult Patients with Sarcoma.

Autor: Wooten SV; Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Amini B; Department of Musculoskeletal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Livingston JA; Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hildebrandt MAT; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chandra J; Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gilchrist SC; Cardiovascular Clinical Trials, LabCorp Drug Development, Houston, Texas, USA., Roth M; Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kleinerman E; Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jazyk: angličtina
Zdroj: Journal of adolescent and young adult oncology [J Adolesc Young Adult Oncol] 2023 Dec; Vol. 12 (6), pp. 821-827. Date of Electronic Publication: 2023 May 04.
DOI: 10.1089/jayao.2023.0006
Abstrakt: Background: Adolescents and young adult (AYA) patients with sarcoma are at heightened risk of reduced physical capacity and disease-related weakness. Sit-to-stand (STS) performance correlates with lower extremity functionality and activities of daily living; however, little is known regarding the relationship between muscular status and STS performance in patients with sarcoma. This study assessed STS performance in patients with sarcoma and the association between STS performance and the skeletal muscle index (SMI) and skeletal muscle density (SMD). Methods: This study included 30 patients with sarcoma (15-39 years old) treated with high-dose doxorubicin. Patients performed the five-times-STS test before starting treatment and 1 year after the baseline test. STS performance was correlated with SMI and SMD. SMI and SMD were quantified using computed tomography scans taken at the level of the 4th thoracic vertebra (T4). Results: Mean performance on the STS test at baseline and 1 year was 2.2-fold and 1.8-fold slower than the age-matched general population, respectively. A lower SMI was associated with worse performance on the STS test ( p  = 0.01). Similarly, lower SMD at baseline was also associated with poorer STS performance ( p  < 0.01). Conclusion: Patients with sarcoma have very poor STS performance at baseline and 1 year, which was accompanied by low SMI and SMD at T4.The inability for AYAs to return to healthy age normative STS standards by 1 year may indicate a need for early interventions to enhance skeletal muscle recovery and promote physical activity during and after treatment.
Databáze: MEDLINE
Externí odkaz: